A tie-up with LaNova was terminated, perhaps in favour of a molecule originated by I-Mab.

Despite seeing dose-limiting toxicities, the group is going higher with its KRAS G12D project.

So far ASP3082 looks no better than Jiangsu HengRui’s straight KRAS G12D inhibitor.

It’s back to school for biotech, with a packed conference schedule.

ASP3082 grabs some early attention among degraders set to feature at ESMO.

The Swiss company is still interested in this antigen, after discontinuing two earlier clinical projects.

April will see the first big scientific meeting of the year, and could herald important data from Immutep and GSK.

A roundup of the first quarter's key oncology drug approvals and rejections.

Not long after starting phase 1, RMC-6236 could be in pivotal trials this year.